Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07361107 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)
A Phase 1 study of Colorectal (Colon or Rectal) Cancer, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07361107 is a Phase 1 study of Colorectal (Colon or Rectal) Cancer that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07361107, a Phase 1 study of Colorectal (Colon or Rectal) Cancer, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, non-randomized, open-label, single-arm pilot study investigating the systemic immune response to histotripsy in patients with colorectal cancer with liver metastasis. Histotripsy is an FDA-approved, non-invasive therapeutic modality for the treatment of liver tumors, including both primary and metastatic lesions. In this study, investigators aim to evaluate the kinetics of peripheral T-cell response following histotripsy of colorectal cancer liver metastases (CRCLM). Given the well-documented immune-tolerant tumor microenvironment of liver metastases and their role in systemic resistance to checkpoint inhibitors, investigators hypothesize that histotripsy-induced tumor disruption will lead to measurable alterations in peripheral T-cell clonal expansion and exhaustion markers. Investigators will assess these changes via serial blood draws before and after histotripsy, with the goal of characterizing the systemic immune impact of local tumor ablation. Findings from this study may inform future combination strategies integrating histotripsy with immunotherapy to enhance treatment response in microsatellite-stable CRC
Conditions Studied
Interventions
- PROCEDURE Histotripsy
Study Locations (1)
New York
- Zuckerberg Cancer Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-09-26 |
| Est. Completion | 2027-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07361107
The ClinicalTrials.gov registry entry for NCT07361107 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal (Colon or Rectal) Cancer appearing as the primary indexed condition, and to 1 intervention - of which Histotripsy is the first listed.
NCT07361107 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07361107 about?
NCT07361107 is a clinical study titled "Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)". This is a single-center, non-randomized, open-label, single-arm pilot study investigating the systemic immune response to histotripsy in patients with colorectal cancer with liver metastasis. Histotripsy is an FDA-approved, non-invasive therapeutic modality for the treatment of liver tumors, includi...
What is the current status of trial NCT07361107?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-09-26. Estimated completion is 2027-09-27.
What conditions does trial NCT07361107 study?
This clinical trial studies the following conditions: Colorectal (Colon or Rectal) Cancer.
What interventions are being tested in trial NCT07361107?
The interventions under investigation include: Histotripsy (PROCEDURE).
Who is sponsoring clinical trial NCT07361107?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07361107 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal (Colon or Rectal) Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
RECRUITING · Phase 1
-
Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.